NO2909340T3 - - Google Patents
Info
- Publication number
- NO2909340T3 NO2909340T3 NO13789899A NO13789899A NO2909340T3 NO 2909340 T3 NO2909340 T3 NO 2909340T3 NO 13789899 A NO13789899 A NO 13789899A NO 13789899 A NO13789899 A NO 13789899A NO 2909340 T3 NO2909340 T3 NO 2909340T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU1200607A HU230680B1 (hu) | 2012-10-19 | 2012-10-19 | Diagnosztikai eljárás |
PCT/HU2013/000101 WO2014060785A2 (en) | 2012-10-19 | 2013-10-18 | DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFα INHIBITOR |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2909340T3 true NO2909340T3 (no) | 2017-12-30 |
Family
ID=89990915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO13789899A NO2909340T3 (no) | 2012-10-19 | 2013-10-18 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20160194709A1 (no) |
EP (1) | EP2909340B1 (no) |
JP (1) | JP2016502400A (no) |
CA (1) | CA2889087C (no) |
DK (1) | DK2909340T3 (no) |
EA (1) | EA037105B1 (no) |
ES (1) | ES2645972T3 (no) |
HU (1) | HU230680B1 (no) |
NO (1) | NO2909340T3 (no) |
PL (1) | PL2909340T3 (no) |
UA (1) | UA118658C2 (no) |
WO (1) | WO2014060785A2 (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016179469A1 (en) * | 2015-05-07 | 2016-11-10 | Abbvie Inc. | Methods and compositions for diagnosing and treating inflammatory bowel disease |
US10752699B2 (en) | 2015-06-29 | 2020-08-25 | Regents Of The University Of Minnesota | Anti-APOBEC3 antibodies and methods of making and using |
GB2547406A (en) * | 2015-11-20 | 2017-08-23 | Folkersen Lasse | Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response |
GB201521357D0 (en) * | 2015-12-03 | 2016-01-20 | Univ Liverpool | Methods for predicting response to anti-TNF therapy |
US20190085405A1 (en) * | 2016-03-23 | 2019-03-21 | Regents Of The University Of Minnesota | Methods of detecting apobec3 expression and predicting clinical outcomes |
EP3755810A4 (en) * | 2018-02-19 | 2022-03-23 | Genefron Ltd. | PROCEDURE FOR DETERMINING RESPONSE TO TNF-ALPHA BLOCKER |
JP2021518432A (ja) | 2018-03-16 | 2021-08-02 | サイファー メディシン コーポレイション | 抗tnf療法に対する応答性を予測するための方法及びシステム |
KR102337232B1 (ko) * | 2018-11-30 | 2021-12-09 | 차의과학대학교 산학협력단 | 뇌 유래 소포체 특이적 마커 및 이를 이용한 뇌 질병 진단 방법 |
JPWO2020116567A1 (ja) * | 2018-12-07 | 2021-12-23 | 株式会社Dnaチップ研究所 | 関節リウマチ治療薬の奏効を予測する方法及びそれに用いるバイオマーカー |
CA3145237A1 (en) | 2019-06-27 | 2020-12-30 | Scipher Medicine Corporation | Developing classifiers for stratifying patients |
KR102429261B1 (ko) * | 2020-08-25 | 2022-08-03 | 충북대학교 산학협력단 | 한국인의 tnf 저해제 약물 반응성 예측을 위한 바이오마커 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3633000A (en) * | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
CA2519870A1 (en) * | 2003-04-09 | 2004-10-28 | Genentech, Inc. | Use of rituximab intravenous compositions to treat rheumatoid arthritis |
EP1857559A1 (en) * | 2006-05-16 | 2007-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for predicting responsiveness to TNF alpha blocking agents |
CN101711286A (zh) * | 2007-04-02 | 2010-05-19 | 健泰科生物技术公司 | 预示类风湿性关节炎对b细胞拮抗剂的响应的生物学标志物 |
WO2008132176A2 (en) * | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
EP2679996A1 (en) * | 2007-05-31 | 2014-01-01 | AbbVie Inc. | Biomarkers predictive of the responsiveness to TNF-alfa inhibitors in autoimmune disorders |
EP2326731B1 (en) * | 2008-08-25 | 2013-11-13 | Janssen Biotech, Inc. | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders |
JP2011004743A (ja) * | 2009-06-26 | 2011-01-13 | Dna Chip Research Inc | 関節リウマチ患者におけるインフリキシマブ薬効の有効性を判別する方法 |
WO2012061620A1 (en) * | 2010-11-04 | 2012-05-10 | Genentech, Inc. | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
-
2012
- 2012-10-19 HU HU1200607A patent/HU230680B1/hu not_active IP Right Cessation
-
2013
- 2013-10-18 CA CA2889087A patent/CA2889087C/en active Active
- 2013-10-18 PL PL13789899T patent/PL2909340T3/pl unknown
- 2013-10-18 UA UAA201504849A patent/UA118658C2/uk unknown
- 2013-10-18 ES ES13789899.5T patent/ES2645972T3/es active Active
- 2013-10-18 US US14/436,705 patent/US20160194709A1/en not_active Abandoned
- 2013-10-18 NO NO13789899A patent/NO2909340T3/no unknown
- 2013-10-18 EA EA201590773A patent/EA037105B1/ru unknown
- 2013-10-18 DK DK13789899.5T patent/DK2909340T3/da active
- 2013-10-18 WO PCT/HU2013/000101 patent/WO2014060785A2/en active Application Filing
- 2013-10-18 JP JP2015537363A patent/JP2016502400A/ja active Pending
- 2013-10-18 EP EP13789899.5A patent/EP2909340B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP2909340B1 (en) | 2017-08-02 |
WO2014060785A3 (en) | 2014-06-12 |
UA118658C2 (uk) | 2019-02-25 |
PL2909340T3 (pl) | 2018-01-31 |
JP2016502400A (ja) | 2016-01-28 |
WO2014060785A2 (en) | 2014-04-24 |
ES2645972T3 (es) | 2017-12-11 |
HU230680B1 (hu) | 2017-08-28 |
CA2889087A1 (en) | 2014-04-24 |
CA2889087C (en) | 2021-11-16 |
EP2909340A2 (en) | 2015-08-26 |
DK2909340T3 (da) | 2017-11-13 |
EA037105B1 (ru) | 2021-02-05 |
EA201590773A1 (ru) | 2015-09-30 |
HUP1200607A2 (en) | 2014-04-28 |
US20160194709A1 (en) | 2016-07-07 |